GSK's expansion strategy through pandemic flu pays off

10/8/2009 | Wall Street Journal, The

GlaxoSmithKline's investment in products to combat H1N1 and bird flu infections has made it a global leader in the market of pandemic flu treatment. The strategy, which expanded GSK's portfolio from drugs and vaccines to diagnostic tools and medicated face masks, is expected to help the drugmaker sustain revenue as patents of its blockbuster drugs near expiration.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC